




BIA Separations

CIMmultus™ Monoliths – tailored to accelerate process development and address large scale manufacturing of ATMPs and Vaccines.

Ingo S. Nagler, BDO

CIMmultus™ Monoliths

A versatile technology platform covering all large, complex vaccine candidates



CIMmultus™ Monoliths

Inherent design properties facilitate yield, productivity and potency




Inherent design properties of BIA's monolith technology...



Continuous structure (sponge-like)

- Consistent channel diameter throughout the entire bed
- Channel volume is about 60% of total monolith volume
- Creates high flows with minimal pressure drop



Convective mass transport; laminar flow


- Capacity and quality of fractionation are independent of flow rate and size of molecule
- Flow runs parallel to its channel walls, precluding eddy formation



Highly interconnected channels


- Laminar flow in monoliths limits solute dispersion to laminar dispersion and dispersion caused by partially lagging solutes of the solute front
- Without irregular cavities, laminar flow is maintained through branching flow paths

...Reduce shear stress, increase yield, and increase productivity




Low shear stress and dispersion; higher resolution

- Absence of a void volume avoids dispersion and shear, two consequences of incumbent methods, leading to higher resolutions and eluted product concentration
- Leads to exponential increases in yield rates by up to 80%



Better productivity

- Continuous and uniform flow throughout the column bed results in greater volumes, faster speeds, and lower pressures within the column
- Monolith technologies results in lower manufacturing costs by as much as 3x when compared to traditional particle (diffusion) columns




Highest binding capacity

- Binding and elution occur at channel surfaces, supporting instantaneous transfer kinetics, contribution to efficient surface utilization (e.g. high binding capacity)
- 10x product yield compared to incumbent methods and a proportional reduction in material costs, production area space, hardware size, etc.

CIMmultus™ Monoliths

Chromatography of large, complex biomolecules by design




CIMmultus™ Monoliths


Monoliths outperform conventional media in **large biomolecule chromatography** applications due to inherent design properties.



Membranes




Monoliths



Flow independent capacity
Flow independent resolution

Porous Particles



CIMmultus™ Monoliths

Monoliths have contributed to 100's of clinical batches of pDNA, including market supply.



40L
CIMmultus™.
Pre-packed.
Multi-Use.



200g
Plasmid DNA
Ultra Pure.
Per cycle.

- COVID pDNA vaccine dosing estimated in low mg range
- [HIP\(2\) Process Pack generic protocol](#)
- Extreme productivity needed
- No compromise in purity
- Analytical technology in place

<https://www.businesswireindia.com/plasmid-dna-manufacturing-technology-co-developed-by-boehringer-ingelheim-austria-with-bia-separations-6924.html>

<https://www.lisavienna.at/news/biomay-and-bia-separations-collaborate-on-production-and-purification-of-large-dna-plasmids/>



CIMmultus™ Monoliths

Monolith based mRNA purification portfolio solves capturing and polishing problem at manufacturing scale



8L
CIMmultus™.
Pre-packed.
Single or Multi-Use.



16g
mRNA
Ultra Pure.
Per cycle.

- COVID mRNA vaccines dosing estimated in 5-200 ug range
- Broad Portfolio of 5 chemistries
- dsRNA impurity removal solved
- No compromise in purity
- Analytical technologies in place

CIMmultus™ Monoliths

Monolith based VLP purification outperforms productivity of density gradient centrifugation based method by factor 200*



- COVID VLP vaccine dosing estimated in E9-E11 range
- Capturing and polishing chemistries in place
- Critical Chromatin impurity removal technology in place
- Analytical technologies in place

• <https://www.sciencedirect.com/science/article/pii/S0021967316306446>

CIMmultus™ Monoliths

Monolith based AAV *purification follows capturing and polishing strategies of Gene Therapy vectors – BIA has large scale market supply experience**



8L
CIMmultus™.
Pre-packed.
Single or Multi-Use.



E17_{vg}
AAV Vector
Ultra Pure.
Per cycle.


- Capturing and polishing chemistries in place
- Critical Chromatin impurity removal technology in place
- Market leading empty/full separation in place
- Analytical technologies in place

*: <https://www.nytimes.com/2020/05/04/health/gene-therapy-harvard-coronavirus.html>

** : <https://bioprocessintl.com/bioprocess-insider/upstream-downstream-processing/bia-separations-providing-chromatography-columns-for-avaxis/>

CIMmultus™ Monoliths

Example of Live Influenza (Flu) Process Intensification



* Capacity is very much depending on the impurity profile of the feedstock. For pure Influenza Virus the capacity would be in the range of E15.



CIMmultus™ Monoliths

Example of Live Influenza (Flu) Process Intensification

Thank you very much for your attention!
For all further questions, please contact:
ingo.nagler@biaseparations.com



Left buliding: current facility
Right building: under construction
Total: 7000 m2